Spun out of UCLA and Caltech, Sofie Biosciences, Inc. develops molecular imaging diagnostics and technologies to enable widespread access to Positron Emission Tomography (PET): molecular imaging scanners, probes and devices designed to support investigation of the biology of disease. Described as a Theranostics firm - a relatively new field of medicine which combines specific targeted therapy based on specific targeted diagnostic tests - Sofie's products are used for diagnosis, staging, and treatment evaluation in oncology, neurology, cardiology, and immunology. Equipment is also used as biomedical research tools providing the means to image small laboratory animals to understand human disease models. The early vision for molecular imaging was to revolutionize clinical diagnostics and therapeutics better to understand and to treat the biology of disease. SOFIE brings that vision to life by increasing the adoption and application diversity of theranostics by removing the cost and complexity traditionally associated with the technology -- a full line of imaging and radiochemistry systems and a premier radiopharmacy network and contract manufacturing organization to supply novel agents for diagnosis and therapy. In 2017, Sophie acquired Zevacor Pharma - previously owned by Illinois Health and Science (IHS). The combined capabilities are intended to provide customers with an ecosystem of PET products from imaging diagnostics to chemistry technologies for manufacturing of new compounds, to PET imaging system
